Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ray Liu

Showing results (91-100 of 100) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 100 results.
European Journal of Medicinal Chemistry|July 2, 2022
A multi-pronged evaluation of aldehyde-based tripeptidyl main protease inhibitors as SARS-CoV-2 antiviralsYuying Ma, Kai S Yang, Zhi Zachary Geng, et al.
Journal of the American Chemical Society|April 14, 2026
Nicotine-Inspired, De Novo-Designed SARS-CoV-2 Main Protease Inhibitors Reveal Unique Chemistry for Covalently Conjugating Both Cysteine and Histidine Residues in the Catalytic DyadSandeep Atla, Veerabhadra Vulupala, Yugendar R Alugubelli, et al.
Journal of Medicinal Chemistry|August 10, 2023
A Systematic Survey of Reversibly Covalent Dipeptidyl Inhibitors of the SARS-CoV-2 Main ProteaseZhi Zachary Geng, Sandeep Atla, Namir Shaabani, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
A Systematic Survey of Reversibly Covalent Dipeptidyl Inhibitors of the SARS-CoV-2 Main ProteaseZhi Zachary Geng, Sandeep Atla, Namir Shaabani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2011
Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignanciesEdmund C Lee, Michael Fitzgerald, Bret Bannerman, et al.
Antiviral Research|March 30, 2024
Azapeptides with unique covalent warheads as SARS-CoV-2 main protease inhibitorsKaustav Khatua, Yugendar R Alugubelli, Kai S Yang, et al.
Nature Communications|February 14, 2026
From nicotine to SARS-CoV-2 antivirals with potent in vivo efficacy and a broad anti-coronavirus spectrumKaustav Khatua, Sandeep Atla, Demonta Coleman, et al.
Biorxiv : the Preprint Server for Biology|April 24, 2023
An Azapeptide Platform in Conjunction with Covalent Warheads to Uncover High-Potency Inhibitors for SARS-CoV-2 Main ProteaseKaustav Khatua, Yugendar R Alugubelli, Kai S Yang, et al.
Chemmedchem|December 7, 2020
A Quick Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors*Kai S Yang, Xinyu R Ma, Yuying Ma, et al.
Biorxiv : the Preprint Server for Biology|August 9, 2020
A Speedy Route to Multiple Highly Potent SARS-CoV-2 Main Protease InhibitorsKai S Yang, Xinyu R Ma, Yuying Ma, et al.
Pageof 10

Showing results (91-100 of 100) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 100 results.
European Journal of Medicinal Chemistry|July 2, 2022
A multi-pronged evaluation of aldehyde-based tripeptidyl main protease inhibitors as SARS-CoV-2 antiviralsYuying Ma, Kai S Yang, Zhi Zachary Geng, et al.
Journal of the American Chemical Society|April 14, 2026
Nicotine-Inspired, De Novo-Designed SARS-CoV-2 Main Protease Inhibitors Reveal Unique Chemistry for Covalently Conjugating Both Cysteine and Histidine Residues in the Catalytic DyadSandeep Atla, Veerabhadra Vulupala, Yugendar R Alugubelli, et al.
Journal of Medicinal Chemistry|August 10, 2023
A Systematic Survey of Reversibly Covalent Dipeptidyl Inhibitors of the SARS-CoV-2 Main ProteaseZhi Zachary Geng, Sandeep Atla, Namir Shaabani, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
A Systematic Survey of Reversibly Covalent Dipeptidyl Inhibitors of the SARS-CoV-2 Main ProteaseZhi Zachary Geng, Sandeep Atla, Namir Shaabani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2011
Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignanciesEdmund C Lee, Michael Fitzgerald, Bret Bannerman, et al.
Antiviral Research|March 30, 2024
Azapeptides with unique covalent warheads as SARS-CoV-2 main protease inhibitorsKaustav Khatua, Yugendar R Alugubelli, Kai S Yang, et al.
Nature Communications|February 14, 2026
From nicotine to SARS-CoV-2 antivirals with potent in vivo efficacy and a broad anti-coronavirus spectrumKaustav Khatua, Sandeep Atla, Demonta Coleman, et al.
Biorxiv : the Preprint Server for Biology|April 24, 2023
An Azapeptide Platform in Conjunction with Covalent Warheads to Uncover High-Potency Inhibitors for SARS-CoV-2 Main ProteaseKaustav Khatua, Yugendar R Alugubelli, Kai S Yang, et al.
Chemmedchem|December 7, 2020
A Quick Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors*Kai S Yang, Xinyu R Ma, Yuying Ma, et al.
Biorxiv : the Preprint Server for Biology|August 9, 2020
A Speedy Route to Multiple Highly Potent SARS-CoV-2 Main Protease InhibitorsKai S Yang, Xinyu R Ma, Yuying Ma, et al.
Pageof 10